Tecovirimat: First Global Approval
- 237 Downloads
Tecovirimat (TPOXX®) is an orthopoxvirus-specific antiviral drug developed by SIGA Technologies in conjunction with the US Department of Health and Human Services’ Biomedical Advances Research and Development Authority. It acts by inhibiting the activity of the orthopoxvirus VP37 envelope wrapping protein, thereby preventing the formation of egress-competent enveloped virions, which are essential for dissemination of the virus in the host. In July 2018, oral tecovirimat was approved in the USA for the treatment of human smallpox disease caused by variola virus in adults and paediatric patients weighing ≥ 13 kg. Tecovirimat was approved under the US FDA’s Animal Rule, in which marketing approval is based on its efficacy in relevant animal models. An intravenous formulation of tecovirimat is undergoing phase I development for the treatment of smallpox infection. This article summarises the milestones in the development of tecovirimat leading to this first approval for the treatment of human smallpox disease in adults and paediatric patients weighing ≥ 13 kg.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sheridan Hoy is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 1.US FDA. FDA approves the first drug with an indication for treatment of smallpox; 2018. http://www.fda.gov/. Accessed 16 July 2018.
- 4.SIGA Technologies Inc. TPOXX (tecovirimat) capsules for oral use: US prescribing information; 2018. http://www.fda.gov/. Accessed 26 July 2018.
- 6.SIGA Technologies Inc. U.S. Food and Drug Administration approves SIGA Technologies’ TPOXX® (tecovirimat) for the treatment of smallpox [media release]. 13 July 2018. http://www.siga.com/.